Lupin: Drug maker Lupin on Tuesday said the US health regulator has cautioned that the firm's Pithampur facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.
ITC, Hotel Leela: Barely a month after Brookfield closed a deal to buy four hotels and a property of Hotel Leelaventure, ITC, which has a 8.72 per cent stake in the hospitality firm, has filed a petition in the National Company Law Tribunal (NCLT), accusing the company of oppression and mismanagement.
Dr Reddy's: Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)